Accessibility Menu
Biora Therapeutics logo

Biora Therapeutics(OTC) BIORQ

Market Cap$500.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-100%
5 Year-100%
1 Year+0%
1 Month-50%
$0.00
+0.00%
+0.00Today
Biora Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-25
Biora Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-18
1 month-50%USD 0.002026-07-24
3 month+0%USD 0.002026-05-27
Year to date+9,900%USD 0.002025-12-31
1 year+0%USD 0.002025-08-25
3 year-100%USD 26.802023-08-25
5 year-100%USD 191.702021-08-26
Since inception-100%USD 3,280.002020-06-19

Biora Therapeutics Financials at a Glance

Market Cap

$500.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.76M

Net Income (TTM)

-$31.54M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

5.35 (High)

Price

$0.00

Volume

8

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 28, 2026

BIORQ News

GettyImages-1264101698

Why Shares of Progenity Are Down More Than 11% on Wednesday

James HalleyDec 1, 2021
Progenia

Why Progenity Stock Is Up More Than 34% Tuesday

James HalleyNov 16, 2021
GettyImages-487041721

Why Progenity Stock Was Up More Than 24% Friday

James HalleyOct 22, 2021
GettyImages-672153331

Why Progenity Stock Is Soaring on Tuesday

James HalleyOct 12, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biora Therapeutics

Biora Therapeutics, Inc. is a biotechnology company focused on developing and commercializing molecular diagnostic products in the United States. The company specializes in targeted oral delivery systems for biotherapeutics and innovative diagnostic tools aimed at improving patient outcomes.

Products and Services
  • PGN-600: An oral formulation of tofacitinib for ulcerative colitis
  • PGN-001: An orally administered variant of adalimumab targeting ulcerative colitis
  • Recoverable Sampling System: An ingestible smart capsule for GI tract analysis
Growth Outlook
  • Collaboration with Ionis Pharmaceuticals to enhance delivery systems
  • Advancements in oral biotherapeutics for inflammatory conditions and diabetes
  • Expanding market potential in molecular diagnostics and therapeutics
Financial Highlights
  • Recent quarterly revenue of 107,000, showing potential for growth
  • Cash and cash equivalents of 67,234,000, providing operational runway
  • Trailing twelve months net income of -13,808,000, indicating ongoing investment in R&D
Biora Therapeutics is positioned in a rapidly evolving biotechnology sector, focusing on innovative solutions for chronic conditions. The company's commitment to research and development is evident in its diverse product pipeline, which includes oral delivery systems and advanced diagnostic tools. Recent collaborations and advancements suggest a strong potential for growth in both therapeutic and diagnostic markets. Financially, while the company is currently operating at a loss, it maintains a significant cash reserve, allowing for continued investment in its innovative projects. The ongoing development of its proprietary technologies may lead to substantial market opportunities in the future.
AI Generated • Aug 23, 2026

Industry

Biotechnology

Sector

Health Care

Employees

58

CEO

Adi Mohanty, MBA

Website

www.bioratherapeutics.com

Headquarters

San Diego, CA 92122, US

BIORQ Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-1678575.00%

Net Income Margin

-3102875.00%

Return on Equity

121.86%

Return on Capital

N/A

Return on Assets

-397.61%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$500.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.52M

Volume

8

Avg. Volume

645.547

Financials (TTM)

Gross Profit

$665.00K

Operating Income

-$60.87M

EBITDA

-$24.06M

Operating Cash Flow

-$5.37M

Capital Expenditure

-$280.00K

Free Cash Flow

-$5.50M

Cash & ST Invst.

$3.20M

Total Debt

$39.65M

Biora Therapeutics Performance Analysis

Biora Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 1,247,000N/A
20222022-12-31USD 305,000-75.5%
20232023-12-31USD 4,000-98.7%
Biora Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-31N/A
Q12024-03-31-37.8%
Q22024-06-30-41.3%
Q32024-09-30-89.9%
Biora Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -643.27N/A
20222022-12-31USD -49.98-92.2%
20232023-12-31USD -78.6957.5%
Biora Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-3187.3%
Q12024-03-3177.4%
Q22024-06-30-185.7%
Q32024-09-30-1160.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

$32.00K

N/A

Gross Profit

$32.00K

+125.6%

Gross Margin

100.00%

N/A

Market Cap

$500.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$8.62

N/A

Employees

58

N/A

Net Income

-$18.40M

+74.9%

EBITDA

-$16.23M

+77.1%

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

$3.20M

-74.6%

Total Debt

$39.65M

-51.9%

Accounts Receivable

$868.00K

+6.1%

Inventory

$0.00

N/A

Long Term Debt

$14.68M

-82.0%

Short Term Debt

$24.97M

+2495.1%

Return on Assets

-3.98%

N/A

Return on Invested Capital

2.11%

N/A

Free Cash Flow

$31.95M

+389.5%

Operating Cash Flow

$31.82M

+388.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ENVBEnveric Biosciences, Inc.
$1.37+0.00%
OCEAOcean Biomedical, Inc.
$0.00+0.00%
HEPAHepion Pharmaceuticals, Inc.
$0.10+79.25%
JSPRJasper Therapeutics, Inc.
$0.70+0.07%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$217.55-0.05%
PCGPG&E
$16.60-0.08%
BITOProShares Trust - ProShares Bitcoin ETF
$10.45-0.03%
IRENIren
$35.45-0.13%

Questions About BIORQ

What is the current price of Biora Therapeutics?

Biora Therapeutics is trading at $0.00 per share.

What is the 52-week range for Biora Therapeutics?

Over the past 52 weeks, Biora Therapeutics has traded between $0.00 and $0.00.

How much debt does Biora Therapeutics have?

As of the most recent reporting period, Biora Therapeutics reported total debt of $39.65M.

How much cash does Biora Therapeutics have on hand?

Biora Therapeutics reported $3.20M in cash and cash equivalents in its most recent financial results.

What is Biora Therapeutics’s dividend yield?

Biora Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services